Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

• By Derrick Gingery

Related Content

Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access

Feb 26 2016

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

FDA Orphan Designations At Record Levels; Resources Need To Keep Up

Feb 29 2016

HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board

Dec 07 2011

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Sep 23 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Oct 07 2016

Related Companies

Sarepta Therapeutics, Inc.

Teva Pharmaceutical Industries Ltd.

Anthem Inc.

Additional Topics

United States Approvals Drug Review Policy BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window